Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus XELOX in locally advanced rectal cancer
NCT05815303Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cadonilimab in rectal cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathological Complete Response Rate at 3 years. Started Mar 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05815303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815303.